Clinical trials: Sjögren Syndrome
Primary Sjögren's Syndrome
A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in participants with primary Sjögren's syndrome (pSjS).
- Trial name
- NCT07727486
- Testing
- ICP-488 Tablets
- Where
- 22 sites in China
- Volunteers
- 240 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
SLE - Systemic Lupus Erythematosus, Systemic Sclerosis
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
This is a single-arm, open-label, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with autoantibody-mediated autoimmune…
- Conditions
- SLE - Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07596680
- Testing
- RD06-05 CAR-T Cell Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Sjogren Syndrome
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
- Trial name
- NEPTUNUS-1 (NCT05350072)
- Testing
- VAY736
- Where
- 77 sites in United States, Austria and 16 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
MTS109 in Patients With Refractory Autoimmune Diseases
This is the first-in-human trial of MTS109 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS109 in moderate to severe autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis (SSc), ANCA-Associated Vasculitis (AAV)
- Trial name
- NCT07526350
- Testing
- MTS109
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Changzheng Hospital
Sjogren's Syndrome
B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome
The objectif is to study the diagnosis performance of the different classification criteria in reference to the gold standard consisting of the diagnosis made by expert doctors after standardized assessment, of pSS (primary…
- Trial name
- BRAISES-DiaPSS (NCT04931160)
- Testing
- Blood, fluid, sells and urine samples
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Brest
Sjogren Syndrome, Sjogren Syndrome With Keratoconjunctivitis
Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease
Sjögren's syndrome is a condition in which the immune system attacks the body's moisture-producing glands. This often causes severe dry eye, leading to discomfort, irritation, blurred vision, and damage to the eye surface.
- Conditions
- Sjogren Syndrome, Sjogren Syndrome With Keratoconjunctivitis, Dry Eye Disease (DED)
- Trial name
- INFLIXIDRY (NCT07671222)
- Testing
- Infliximab 0.1%, Loteprednol
- Where
- Mexico
- Volunteers
- 38 people
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana
Primary Sjögren Syndrome
Inflammatory Myopathies in Primary Sjögren's Syndrome
The AMISS study will characterize the features of muscle disease in patients with primary Sjogren's syndrome (pSS).
- Trial name
- AMISS (NCT03126383)
- Where
- France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Brest
Systemic Lupus Erythematosus
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
This is a 2-part study of GSK5926371 in participants with autoimmune rheumatic diseases (ARD). In part 1, participants will receive different doses of GSK5926371 to find a suitable priming dose.
- Trial name
- ELEVATE-1 (NCT07371468)
- Testing
- GSK5926371
- Where
- 19 sites in Argentina, Brazil and 7 more
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Sjogren Syndrome
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
- Trial name
- NEPTUNUS-2 (NCT05349214)
- Testing
- VAY736
- Where
- 146 sites in United States, Argentina and 24 more
- Volunteers
- 506 people
- Sponsor
- Novartis Pharmaceuticals
Primary Sjögren's Syndrome (pSS)
CM336 for Active Sjogren's Syndrome Study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CM336 in adult participants with active primary Sjogren's Syndrome.
- Trial name
- NCT07642843
- Testing
- CM336
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Keymed Biosciences Co.Ltd
Sjogren's Syndrome
Comprehensive Evaluation of Clinical and Biopsychosocial Characteristics in Primary Sjögren's Disease
Following the guidance of individuals with primary Sjögren's Syndrome who receive diagnosis, routine medical care, and treatment management, the evaluations will be performed once by the researchers and will take approximately…
- Trial name
- NCT06410742
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
A Study of BEN301 Injection in theTreatment of Autoimmune Diseases
The study aims to investigate the safety, tolerability, and preliminary clinical efficacy of BEN301 Injection in patients with autoimmune diseases.
- Conditions
- Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Sjogren's Syndrome (SS), Idiopathic Inflammatory Myopathies(IIM)
- Trial name
- NCT07527936
- Testing
- Single administration of 1x10^8 viable CD4+ CAR+ Foxp3+ cells., Single administration of 3x10^8 viable CD4+ CAR+ Foxp3+ cells.
- Where
- China
- Volunteers
- 24 people
- Sponsor
- RenJi Hospital
Primary Sjögren's Syndrome
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Primary Sjögren's Syndrome.
- Trial name
- NCT04078386
- Testing
- RC18 240 mg, RC18 160 mg
- Where
- 14 sites in China
- Volunteers
- 42 people
- Sponsor
- RemeGen Co., Ltd.
Sjogren's Syndrome
Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome
The study aims at defining the role of immune cells derived from the intestine in the pathogenesis of Sjogren's disease. This research might open new therapeutic approaches for the treatment of autoimmune diseases.
- Trial name
- SINGOU (NCT03841318)
- Testing
- blood sample, biopsy of the labial salivary gland
- Where
- France
- Volunteers
- 57 people
- Sponsor
- University Hospital, Bordeaux
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren's Syndrome
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).
- Trial name
- NCT06312020
- Testing
- HZN-1116
- Where
- 66 sites in United States, Argentina and 14 more
- Volunteers
- 209 people
- Sponsor
- Amgen
Primary Sjögren's Syndrome
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
Primary Sjögren's syndrome (pSS) can affect various organs, sometimes leads to life-threatening conditions and is always responsible for a decreased quality of life.
- Trial name
- I GET DRY (NCT03003572)
- Testing
- Blood samples
- Where
- 8 sites in France
- Volunteers
- 185 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Sjogren-Larsson Syndrome
ADX-629 Therapy for Sjogren-Larsson Syndrome
This research study will determine whether orally administered ADX-629 is safe and has biochemical efficacy in participants with Sjögren-Larsson syndrome (SLS), a rare inherited disorder of fatty aldehyde metabolism The disease…
- Trial name
- NCT05443685
- Testing
- ADX-629
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Nebraska
Sjogren's Syndrome, Non-celiac Gluten Sensitivity
Wheat-free Diet in the Treatment of Sjogren's Syndrome
Recent data show that some foods can increase intestinal mucosa permeability and immune activation of subjects with gastrointestinal (GI) symptoms.
- Trial name
- NCT05644795
- Testing
- Wheat/milk free diet (W/MFD) group, Rice/turkey free diet (R/TFD) group
- Where
- 3 sites in Italy
- Volunteers
- 30 people
- Sponsor
- University of Palermo
Sjogren's Syndrome
Immune Profile of Saliva and Serum of Patients With Primary Sjögren´s Syndrome
Primary Sjögren's syndrome (pSS) is a chronic systemic inflammatory disease, which mainly affects the lacrimal and salivary glands, leading to sicca syndrome.
- Trial name
- pSS (NCT03711214)
- Testing
- Periodontal scaling
- Where
- 3 sites in Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital